A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the DNA Polymerase Theta Inhibitor ART6043 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors
NCT #
NCT05898399
Condition(s)
Breast Cancer, Solid Tumor
Molecular Target(s)
Polθ
Drug Classification(s)
Molecular Targeted Therapy, Small Molecule
Agents(s)
Phase I, Open-Label, Multinational, Multicenter, Dose Escalation and Expansion Study of BH3120 in Patients with Advanced or Metastatic Solid Tumors
Phase(s)
I/Iia
Mechanism of Action
ART6043 is a Polθ inhibitor
Purpose
- How much of the study drug can be given alone and in combination with Olaparib or Talazoparib with an acceptable level of side effects
- The effects of the study drug alone and in combination with Olaparib or Talazoparib (good and bad)
- How much of the study drug is absorbed into the blood and how fast it is removed
- How the study drug is acting on your body, on tumors and the substances in your body that can be used to monitor how your disease is doing
- If research tests can be used in the future to predict who will benefit from the study drug when given alone or in combination with Olaparib or Talazoparib
Location
MCD
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.